S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10

Seagen (SGEN) Stock Forecast, Price & News

+2.93 (+2.12%)
(As of 05/27/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
1.03 million shs
Average Volume
1.13 million shs
Market Capitalization
$26.03 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive SGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for Seagen and its competitors with MarketBeat's FREE daily newsletter.

Seagen logo

About Seagen

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.


Seagen says CEO has resigned - MarketWatch
Seagen Board Accepts Resignation Of Clay Siegall - Quick Facts
See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$1.57 billion
Book Value
$16.29 per share


Net Income
$-674.47 million
Pretax Margin




Free Float
Market Cap
$26.03 billion

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Social Links


Overall MarketRank

2.31 out of 5 stars

Medical Sector

264th out of 1,424 stocks

Biological Products, Except Diagnostic Industry

43rd out of 209 stocks

Analyst Opinion: 2.4Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.6 5 -4 -3 -2 -1 -

Seagen (NASDAQ:SGEN) Frequently Asked Questions

Is Seagen a buy right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Seagen in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Seagen stock.
View analyst ratings for Seagen
or view top-rated stocks.

When is Seagen's next earnings date?

Seagen is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Seagen

How were Seagen's earnings last quarter?

Seagen Inc. (NASDAQ:SGEN) posted its quarterly earnings results on Thursday, April, 28th. The biotechnology company reported ($0.74) EPS for the quarter, beating analysts' consensus estimates of ($0.98) by $0.24. The biotechnology company earned $426.50 million during the quarter, compared to analyst estimates of $401.75 million. Seagen had a negative trailing twelve-month return on equity of 21.86% and a negative net margin of 41.32%. The company's quarterly revenue was up 28.5% on a year-over-year basis. During the same quarter last year, the firm earned ($0.67) EPS.
View Seagen's earnings history

What guidance has Seagen issued on next quarter's earnings?

Seagen issued an update on its FY 2022 earnings guidance on Monday, May, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.67 billion-$1.75 billion, compared to the consensus revenue estimate of $1.78 billion.

What price target have analysts set for SGEN?

10 equities research analysts have issued 12-month price targets for Seagen's stock. Their forecasts range from $132.00 to $200.00. On average, they anticipate Seagen's stock price to reach $160.00 in the next year. This suggests a possible upside of 13.2% from the stock's current price.
View analysts' price targets for Seagen
or view top-rated stocks among Wall Street analysts.

Who are Seagen's key executives?
Seagen's management team includes the following people:
  • Dr. Clay B. Siegall Ph.D., Co-Founder, Chairman, Pres & CEO (Age 61, Pay $3.09M)
  • Mr. Todd E. Simpson, Chief Financial Officer (Age 61, Pay $1.17M)
  • Ms. Jean I. Liu J.D., M.S., Chief Legal Officer (Age 54, Pay $1.11M) (LinkedIn Profile)
  • Mr. Charles R. Romp, Exec. VP of Commercial U.S. (Age 54, Pay $1.02M) (LinkedIn Profile)
  • Dr. Roger D. Dansey M.D., Chief Medical Officer (Age 66, Pay $1.53M) (LinkedIn Profile)
  • Dr. Vaughn B. Himes Ph.D., Chief Technical Officer (Age 61)
  • Peggy Pinkston, Sr. VP of Investor Relations
  • Mr. David Caouette, VP of Corp. Communications
  • Ms. Natasha A. Hernday, Exec. VP of Corp. Devel. & Alliance Management (Age 50)
  • Mr. Matt Skelton, VP of Marketing
What is Clay B. Siegall's approval rating as Seagen's CEO?

107 employees have rated Seagen CEO Clay B. Siegall on Glassdoor.com. Clay B. Siegall has an approval rating of 99% among Seagen's employees. This puts Clay B. Siegall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Seagen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Seagen investors own include NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Salesforce (CRM), QUALCOMM (QCOM), Tesla (TSLA), Micron Technology (MU), Netflix (NFLX) and Alibaba Group (BABA).

What is Seagen's stock symbol?

Seagen trades on the NASDAQ under the ticker symbol "SGEN."

Who are Seagen's major shareholders?

Seagen's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Capital International Investors (8.40%), BlackRock Inc. (7.44%), Wellington Management Group LLP (6.78%), Vanguard Group Inc. (6.67%), Primecap Management Co. CA (2.51%) and State Street Corp (1.92%). Company insiders that own Seagen stock include Bros Advisors Lp Baker, Charles R Romp, Charles R Romp, Clay B Siegall, Clay B Siegall, Daniel G Welch, David W Gryska, David W Gryska, Jean I Liu, Jean I Liu, Morgan E Obrien, Roger D Dansey, Roger D Dansey, Todd E Simpson, Todd E Simpson, Vaughn B Himes and Vaughn B Himes.
View institutional ownership trends for Seagen

Which major investors are selling Seagen stock?

SGEN stock was sold by a variety of institutional investors in the last quarter, including ANTIPODES PARTNERS Ltd, Mirae Asset Global Investments Co. Ltd., TD Asset Management Inc., UBS Group AG, First Trust Advisors LP, Tobam, Tekla Capital Management LLC, and Rhenman & Partners Asset Management AB. Company insiders that have sold Seagen company stock in the last year include Bros Advisors Lp Baker, Charles R Romp, Clay B Siegall, David W Gryska, Jean I Liu, Morgan E Obrien, Roger D Dansey, Todd E Simpson, and Vaughn B Himes.
View insider buying and selling activity for Seagen
or view top insider-selling stocks.

Which major investors are buying Seagen stock?

SGEN stock was purchased by a variety of institutional investors in the last quarter, including Capital International Investors, Wellington Management Group LLP, Woodline Partners LP, BlackRock Inc., Capital Group Private Client Services Inc., Eagle Health Investments LP, Artal Group S.A., and Vanguard Group Inc..
View insider buying and selling activity for Seagen
or or view top insider-buying stocks.

How do I buy shares of Seagen?

Shares of SGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Seagen's stock price today?

One share of SGEN stock can currently be purchased for approximately $141.39.

How much money does Seagen make?

Seagen has a market capitalization of $26.03 billion and generates $1.57 billion in revenue each year. The biotechnology company earns $-674.47 million in net income (profit) each year or ($3.770010) on an earnings per share basis.

How many employees does Seagen have?

Seagen employs 2,675 workers across the globe.

Does Seagen have any subsidiaries?

The following companies are subsidiares of Seagen: Cascadian Therapeutics.

When was Seagen founded?

Seagen was founded in 1998.

What is Seagen's official website?

The official website for Seagen is www.seattlegenetics.com.

How can I contact Seagen?

Seagen's mailing address is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. The biotechnology company can be reached via phone at (425) 527-4000, via email at [email protected], or via fax at 425-527-4001.

This page was last updated on 5/28/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.